SECURA-3 Aptamer Details
ID# 8082
Structure
Chemistry
RNA
Target
Pituitary tumour transforming gene 1 (PTTG1)
Category
Protein
Affinity (Kd)
16.41 ± 6.4 nM
Length
99
Aptazyme
No
Sequence (3-char table code)
G
A
C
U/T
5’- rGprGprAprGprCprUprCprAprGprCprCprUprUprCprAprCprUprGprCprGprAprUprCprAprCprCprGprUprGprUprCprGprGprUprGprGprCprUprAprGprUprCprGprAprUprGprUprAprUprCprCprCprGprAprUprCprAprCprCprAprUprUprGprGprGprGprGprCprAprAprGprUprUprUprAprGprAprCprAprGprGprCprAprCprCprAprCprGprGprUprCprGprGprAprUprCprCprAprCp -3'
Molecular Weight: 30229.1
Extinction Coefficient: 907400
Binding Conditions / Buffer
20 mM Tris-HCl (pH 8.6), 8 M Urea, 150 mM NaCl, 10% Glycerol, 1.5X Roche Protease Inhibitor Cocktail EDTA-free).
10 mM HEPES-KOH (pH 7.4) and 150 mM NaCl
Binding Temp: 95, 25°C
Refolding Protocol
If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Reference
Prabu, S. S., Ch’ng, E. S., Woon, P. Y., Chen, J.-H., Tang, T.-H., & Citartan, M. (2020). Unravelling the diagnostic and therapeutic potentialities of a novel RNA aptamer isolated against human pituitary tumour transforming gene 1 (PTTG1) protein. Analytica Chimica Acta. doi:10.1016/j.aca.2020.09.038
Request a Quote
Have your aptamer oligo synthesized by Aptagen.
